Lymphoplasmacytic lymphoma surgery

Lymphoplasmacytic lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Lymphoplasmacytic Lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Lymphoplasmacytic lymphoma surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Lymphoplasmacytic lymphoma surgery
CDC on Lymphoplasmacytic lymphoma surgery
Lymphoplasmacytic lymphoma surgery in the news
Blogs on Lymphoplasmacytic lymphoma surgery
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Lymphoplasmacytic lymphoma surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]

Overview

Surgery is not the first-line treatment option for patients with Waldenström macroglobulinemia. Stem cell transplant is usually reserved for patients with either relapse or refractory Waldenström macroglobulinemia.

Surgery

• Stem cell transplant is usually reserved for patients when either lymphoma comes back (recurs/relapses) after treatment or doesn’t respond to other treatments (called refractory disease).
• Many people with lymphoplasmacytic lymphoma are older or may not be in good health, so a stem cell transplant may not be a good treatment option for them.